RT @ASchmaier: ACE/ARB use before & during (!) hospitalization associated with decreased mortality in #COVID19 in retrospective analysis @…
RT @RogueRad: ACEI/ARB is associated with lower mortality in COVID. Does this study sufficiently debunk the opposite? https://t.co/UINi6JEG…
RT @EmiliSanAlv: Intentaremos confirmar esos datos en el Registro COVID-19 de la @SENefrologia. Cuantos más pacientes incluidos mejor. Grac…
RT @influenzer3: ●ACEI/ARBの使用はCOVID-19における予後良好因子 →これが三報目でかつ決定版かと。 もうこれについては決着がついたと言えるように思います。 https://t.co/DkbC4lpprr
The conclusion may be different. Unfortunately, the use of traditional Chinese medicine has not been effective.
RT @cocoopsi: Buen apunté de nuestro compañeros de @catcardiocamfic. #quedatantoporsaber #covid_19
An important observation. Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19 | Circulation Research https://t.co/258BApoGm
RT @CircRes: Are ACE/ARB inhibitors safe for #COVID19 patients? https://t.co/FGsCthPS24 A new observational study suggests that use of #A…
Buen apunté de nuestro compañeros de @catcardiocamfic. #quedatantoporsaber #covid_19
RT @DrLoomba: We are starting a randomized controlled trial comparing Ramipril versus placebo for prevention of mortality due to COVID-19--…
@gyrfalc63587709 @Rectitude20 I remember when he said that. It was a month ago, maybe more. It was speculation. It needed study. Now they have done some studies, they have shown no link. https://t.co/L7jvomr4ba https://t.co/nYu41S1xcw https://t.co/Bj
@dris3af @EchoMoonBeam @CNN @andrewcuomo @realDonaldTrump @FoxNews @POTUS @CDCDirector @NIH @RandPaul @tedcruz @SenTedCruz Can you provide any data/studies that found a worse outcome for patients usings ACE Inhibitors? I can post a few recent ones showin
RT @ManuelGorostidi: IECAs y ARA2 durante la hospitalización por #COVID19 👌🏽Mejor pronóstico @SENefrologia @SEHLELHA140_90 @SEMERGENap @sec…
RT @CarlosdelRio7: Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Morta…
Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19 | Circulation Research https://t.co/fuLfiAvYiO
ACEI/ARB Treatment Tied To 58% Lower Death Rate In Patients With #Hypertension In Hospitalized Patients With #CoVid19, Analyses Show https://t.co/V6cWo6d10r
RT @EmiliSanAlv: Intentaremos confirmar esos datos en el Registro COVID-19 de la @SENefrologia. Cuantos más pacientes incluidos mejor. Grac…
Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19 | Circulation Research https://t.co/sUV021zZMY
RT @ManuelGorostidi: IECAs y ARA2 durante la hospitalización por #COVID19 👌🏽Mejor pronóstico @SENefrologia @SEHLELHA140_90 @SEMERGENap @sec…
RT @catcardiocamfic: En pacients hospitalitzats amb #COVID19 amb HTA, l’us d’IECA/ARA2 es va associar a menor mortalitat que en els que no…
RT @DrRoderickTung: Nice illustration of how initial speculation based on isolated physiological upregulation of ACE2 may actually be the…
RT @EmiliSanAlv: Intentaremos confirmar esos datos en el Registro COVID-19 de la @SENefrologia. Cuantos más pacientes incluidos mejor. Grac…
RT @CarlosdelRio7: Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Morta…
Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19 | Circulation Research https://t.co/RjOL3xMGH9
RT @DrLoomba: This our paper with Wuhan group showing benefits of ACE inhibitors and ARB in COVID-19 https://t.co/cdgjeQUUqq
RT @DrLoomba: This our paper with Wuhan group showing benefits of ACE inhibitors and ARB in COVID-19
RT @EmiliSanAlv: Intentaremos confirmar esos datos en el Registro COVID-19 de la @SENefrologia. Cuantos más pacientes incluidos mejor. Grac…
RT @EmiliSanAlv: Intentaremos confirmar esos datos en el Registro COVID-19 de la @SENefrologia. Cuantos más pacientes incluidos mejor. Grac…
Intentaremos confirmar esos datos en el Registro COVID-19 de la @SENefrologia. Cuantos más pacientes incluidos mejor. Gracias
RT @96hage: 高血圧症の新型コロナウイルス感染(COVID-19)患者1128人を調べたところ、ACEI/ARB使用群の死亡率は3.7%、非使用群は9.8%(P = 0.01)。年齢・性別・合併症・服用薬で補正してもACEI/ARB使用群の死亡率は58%低い(ハザード…
高血圧症の新型コロナウイルス感染(COVID-19)患者1128人を調べたところ、ACEI/ARB使用群の死亡率は3.7%、非使用群は9.8%(P = 0.01)。年齢・性別・合併症・服用薬で補正してもACEI/ARB使用群の死亡率は58%低い(ハザード比0.42; P =0.03)。 https://t.co/w70gV4bsf6
ACEI/ARB users vs non-users associated with lower adjusted risk of all-cause mortality among hospitalized COVID-19 patients with hypertension https://t.co/lc0ag6V22c #COVID19 #COVID19Rx
@UCSDnews @UCSDMedSchool UCSD working in collaboration with Pfizer @pfizer is launching a large RCT comparing Ramipril versus placebo for COVID-19 @CovidHep @COVID19Tracking
Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19 | Circulation Research https://t.co/3xEN3t7sW8
RT @doc_ibd: Inpatient Use of ACE Inhibitors and Angiotensin II R Blockers decreased mortality in COVID-19. Sig. interest in whether this w…
RT @CarlosdelRio7: Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Morta…
Link(s): ARB and ACE inhibitor study in JAMA Cardiology (Free) https://t.co/8reiv2HqNz ARB and ACE inhibitor study in Circulation Research (Free) https://t.co/kxdgJGJ8o2 CDC news release on cats (Free) https://t.co/MEiAoZzal6 (cont)
RT @CarlosdelRio7: Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Morta…
RT @EMPoisonPharmD: Observational data to refute the conjectural statement in the the lancet letter 3/11 of possible worse outcomes with AC…
Observational data to refute the conjectural statement in the the lancet letter 3/11 of possible worse outcomes with ACE and ARB use in COVID19 Lancet opinion https://t.co/jtWpEKc7ID Refuting Obssrvational study: https://t.co/oplKz6Y01Q #covid19
RT @MD_AlQaysi: ACEI/ARB was associated with lower risk of all-cause mortality among hospitalized patients with HTN with COVID-19 | Circu…
@IlindelatorreMD Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19 | Circulation Research https://t.co/K7bGOlJPCS
RT @DrLoomba: This our paper with Wuhan group showing benefits of ACE inhibitors and ARB in COVID-19
RT @SantasEnrique: Datos que de nuevo refuerzan NO suspender IECA/ARA-2 en pacientes con HTA 🏥 por #COVID19. Menor riesgo de mortalidad e…
Fingers crossed!
RT @CarlosdelRio7: Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Morta…
RT @CarlosdelRio7: Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Morta…
RT @DrLoomba: This our paper with Wuhan group showing benefits of ACE inhibitors and ARB in COVID-19
This our paper with Wuhan group showing benefits of ACE inhibitors and ARB in COVID-19
RT @CarlosdelRio7: Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Morta…
@IngrahamAngle another variable likely overlooked in the #hydroxychloriquine bashing #FakeScience paper cited on #FakeNews : https://t.co/TJsJpmdBgF
RT @ABsteward: Surprising! @CircRes @CircAHA Among hospitalized COVID-19 patients with hypertension, inpatient use of ACEI/ARB was associat…
RT @CarlosdelRio7: Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Morta…
RT @CarlosdelRio7: Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Morta…
RT @CarlosdelRio7: Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Morta…
RT @CarlosdelRio7: Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Morta…
RT @CarlosdelRio7: Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Morta…
Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19 | Circulation Research https://t.co/f6hpDowtVO. Use of ARB/ACEis associ
Keep taking ACEI/ARB antihypertensive medication: Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors & Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19 | Circulation Resea
Preprint retrospective study out of China possibly indicating either no effect or *protective* effect of ARBs/ACE inhibitors in hypertensive COVID-19 patients compared to untreated or treated with other antihypertensive agents (usual caveats apply): https
RT @vass_vassiliou: Article in @CircAHA Research indicating ACE I associate with better prognosis in #COVID19 .... https://t.co/cM4nnbb0px…
RT @ABsteward: Surprising! @CircRes @CircAHA Among hospitalized COVID-19 patients with hypertension, inpatient use of ACEI/ARB was associat…
Some good news on the ACEi/ARB front https://t.co/LLFdZkhFPL
@EBondarsky @JAMA_current There's also this: https://t.co/UIFvUmUViy
ACEI/ARB was associated with lower risk of all-cause mortality among hospitalized patients with HTN with COVID-19 | Circulation https://t.co/7phc46Tj1V
RT @ABsteward: Surprising! @CircRes @CircAHA Among hospitalized COVID-19 patients with hypertension, inpatient use of ACEI/ARB was associat…
For all of you wondering if you ACE2 inhibitor, like Losartan, is good or bad........You should probably keep taking it. It seems to signifiicantly reduce mortality. It also intuitively makes sense. https://t.co/2CXKCPVnXe
RT @ManuelGorostidi: IECAs y ARA2 durante la hospitalización por #COVID19 👌🏽Mejor pronóstico @SENefrologia @SEHLELHA140_90 @SEMERGENap @sec…
Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19 | Circulation Research #COVID19 #coronavirus #covidcardiology https:/
@reverendofdoubt @Neil_Mehta https://t.co/k9XyDYrQTb This paper was done to look at this specific question. Similarly retrospective confounded etc etc but much better statistical analysis.
Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19 | Circulation Research https://t.co/JkbuBpcFeg
Covid19 requires ACE2 receptor to enter cells. Study from China suggests the possibility that hypertensive patients taking ACE-I / ARB rx have lower mortality. CIRCRESAHA.120.317134 https://t.co/vVfQbqF0OH
Circulation Research https://t.co/ztMfgk3ysI
RT @vass_vassiliou: Article in @CircAHA Research indicating ACE I associate with better prognosis in #COVID19 .... https://t.co/cM4nnbb0px…
Association of Inpatient Use of #ACEIs and #ARBs with Mortality Among Patients With Hypertension Hospitalized With #COVID19 @American_Heart @CircRes https://t.co/wVfeLo1GNE Via @DrLoomba https://t.co/ejp3ZHJ0b5
@ethanjweiss Saw this recently too... https://t.co/uLSB5oJx7b
RT @ManuelGorostidi: IECAs y ARA2 durante la hospitalización por #COVID19 👌🏽Mejor pronóstico @SENefrologia @SEHLELHA140_90 @SEMERGENap @sec…
RT @vass_vassiliou: Article in @CircAHA Research indicating ACE I associate with better prognosis in #COVID19 .... https://t.co/cM4nnbb0px…
RT @ManuelGorostidi: IECAs y ARA2 durante la hospitalización por #COVID19 👌🏽Mejor pronóstico @SENefrologia @SEHLELHA140_90 @SEMERGENap @sec…
RT @vass_vassiliou: Article in @CircAHA Research indicating ACE I associate with better prognosis in #COVID19 .... https://t.co/cM4nnbb0px…
RT @jennkwanMDPhD: Long awaited: retrospective multi-center study of 1128 pts in🇨🇳 @CircAHA using multivariate modeling: ACEI/ARB use assoc…
RT @jennkwanMDPhD: Long awaited: retrospective multi-center study of 1128 pts in🇨🇳 @CircAHA using multivariate modeling: ACEI/ARB use assoc…
RT @urenacard: Menor mortalidad con uso de BRAs o IECAs Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angio…
RT @vass_vassiliou: Article in @CircAHA Research indicating ACE I associate with better prognosis in #COVID19 .... https://t.co/cM4nnbb0px…
Published analysis of ACEI/ARBs in well done propensity-matched analysis, showing substantial reduction in death rates for patients on ACEI/ARBs (but doesn't distinguish the two). You are not going to see a placebo-controlled study. This is where #RWE is
RT @urenacard: Menor mortalidad con uso de BRAs o IECAs Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angio…
RT @vass_vassiliou: Article in @CircAHA Research indicating ACE I associate with better prognosis in #COVID19 .... https://t.co/cM4nnbb0px…
RT @vass_vassiliou: Article in @CircAHA Research indicating ACE I associate with better prognosis in #COVID19 .... https://t.co/cM4nnbb0px…
RT @jennkwanMDPhD: Long awaited: retrospective multi-center study of 1128 pts in🇨🇳 @CircAHA using multivariate modeling: ACEI/ARB use assoc…
A retrospective, multi-center study included 1128 #covid19 patients shows that lower risk of mortality in patients who received ACEI/ARB versus those who did not receive ACEI/ARB. https://t.co/LJ9GZAK2Sd https://t.co/SzREfkac5I
RT @urenacard: Menor mortalidad con uso de BRAs o IECAs Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angio…
RT @jennkwanMDPhD: Long awaited: retrospective multi-center study of 1128 pts in🇨🇳 @CircAHA using multivariate modeling: ACEI/ARB use assoc…
Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19 | Circulation Research https://t.co/zpqBrLDqzo
Long awaited: retrospective multi-center study of 1128 pts in🇨🇳 @CircAHA using multivariate modeling: ACEI/ARB use associated w/58% ⬇️ Death Rate in Patients w/HTN in Hospitalized #COVID19 Patients. Reproduce findings in 🇺🇸? https://t.co/yqt0EFkUNL @drbrow
RT @vass_vassiliou: Article in @CircAHA Research indicating ACE I associate with better prognosis in #COVID19 .... https://t.co/cM4nnbb0px…